Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03959527
Other study ID # STI_Zoli001
Secondary ID 2019-000990-22
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 6, 2019
Est. completion date December 10, 2023

Study information

Verified date May 2023
Source Global Antibiotics Research and Development Partnership
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated gonorrhoea.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1092
Est. completion date December 10, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Age = 12 years old (if enrolment of minors is in agreement with local regulations and thics guidance) 2. Weight = 35 kg 3. Signs and symptoms consistent with urethral or cervical gonorrhoea OR Urethral or cervical uncomplicated gonorrhoea as determined by either a positive culture or NAAT or Gram stain or methylene blue test/gentian violet stain in the past 14 days prior to screening OR Unprotected sexual contact with an individual reported to be infected with NG in the past 14 days prior to screening (confirmation by a positive NAAT, Gram stain or methylene blue test/ gentian violet stain or culture) 4. For females of child-bearing potential, a negative urine pregnancy test at screening 5. For females of child bearing potential, use of highly effective contraception for at least 28 days prior to screening and during at least 28 days after treatment. Females on oral contraceptives must also use a barrier contraception method during participation in the study. 6. For males with a female partner of child-bearing age, willingness to delay conception for 28 days after treatment 7. Willingness to comply with trial protocol 8. Willingness to undergo HIV testing 9. Willingness to abstain from sexual intercourse or use condoms for vaginal, anal and oral sex until end of trial visit 10. Willingness and ability to give written informed consent or be consented by a legal representative or provide assent and parental consent (for minors, as appropriate). Exclusion Criteria: 11. Confirmed or suspected complicated or disseminated gonorrhoea 12. Pregnant or breastfeeding women 13. Known concomitant infection which would require immediate additional systemic antibiotics with activity against NG (e.g. CT infection) 14. Use of any systemic or intravaginal antibiotics with activity against NG within 30 days prior to screening 15. Use of systemic corticoid drugs or other immunosuppressive therapy within 30 days prior to screening 16. Use of moderate or strong CYP3A4 inducers (e.g. efavirenz, rifampicin, carbamazepine, phenobarbital) within 30 days or five half-lives of the drug, whichever is greater, prior to screening 17. Cytotoxic or radiation therapy within 30 days prior to screening 18. Known chronic renal, hepatic, hematologic impairment or other condition interfering with the absorption, distribution or elimination of the drug based on medical history and physical examination 19. History of urogenital sex-reassignment surgery 20. Immunosuppression as evidenced by medical history, clinical examination or a recent (= 1 month) CD4 count <200 cells/µL 21. Know clinically relevant cardiac pro-arrhythmic conditions such as cardiac arrhythmia, congenital or documented QT prolongation 22. Known history of severe allergy to cephalosporin, penicillin, monobactams, carbapenems or macrolide antibiotics 23. Known or suspected allergies or hypersensitivities to lidocaine, methylparaben, lactose or any of the components of the study drugs (refer to the zoliflodacin IB and SmPC for the comparators treatments) 24. Receipt or planned receipt of an investigational product in a clinical trial within 30 days or five half-lives of the drug, whichever is greater, prior to screening until end of participation to this clinical trial 25. History of alcohol or drug abuse within 12 months prior to screening which would compromise trial participation in the judgment of the investigator 26. Severe medical or psychiatric condition which, in the opinion of the investigator, may increase the risk associated with trial participation or may interfere with the interpretation of trial results or affect the individual's ability to provide informed consent 27. Individuals whom, in the judgement of the investigator, are unlikely or unable to comply with this trial protocol 28. Previous randomisation in this clinical trial. 29. Use of moderate or strong CYP3A4 inhibitors within 30 days or five half-lives of the drug, whichever is greater, prior to screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
zoliflodacin
Dose: 3g, oral administration
ceftriaxone
Dose: 500mg, Intra-Muscular (IM) administration
azithromycin
Dose: 1g, oral administration

Locations

Country Name City State
Belgium Institute of Tropical Medicine Antwerp
Netherlands Public Health Service (GGD) Amsterdam / STI Outpatient Clinic Amsterdam
South Africa SAMRC Botha's Hill Clinical Research Site Bothas Hill
South Africa Masiphumelele Research Site Cape Town
South Africa Ndlovu Research Centre Elandsdoorn
South Africa Wits RHI Johannesburg
South Africa Setshaba Research Centre Soshanguve
South Africa SAMRC Tongaat Clinical Research Site Tongaat
Thailand Bangrak STI Center Bangkok
Thailand Institute of HIV Research and Innovation Bangkok
Thailand Silom Community Clinic Bangkok
United States Jefferson County Department of Health Birmingham Alabama
United States University of Alabama at Birmingham Birmingham Alabama
United States Bell Flower Clinic Indianapolis Indiana
United States Louisiana State University Health Sciences Center New Orleans Louisiana
United States San Francisco Department Of Public Health City Clinic San Francisco California
United States Public Health - Seattle & King County STD Clinic Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Global Antibiotics Research and Development Partnership

Countries where clinical trial is conducted

United States,  Belgium,  Netherlands,  South Africa,  Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of a single dose of zoliflodacin will be assessed compared to a combination of a single dose of ceftriaxone and azithromycin. Microbiological cure as determined by culture at urethral or cervical sites at test of cure visit. Day 6
Secondary Safety of a single dose of zoliflodacin will be assessed compared to a combination a single dose of ceftriaxone and azithromycin. Adverse events will be assessed. Day 6 and Day 30
Secondary Microbiological cure rate of pharyngeal gonorrhoea will be determined after administration of a single dose of zoliflodacin compared to a combination of a single dose of ceftriaxone and azithromycin. Proportion of participants with microbiological cure as determined by culture at pharyngeal sites at test of cure visit. Day 6
Secondary Microbiological cure rate of rectal gonorrhoea will be determined after administration of a single dose of zoliflodacin compared to a combination of a single dose of ceftriaxone and azithromycin. Proportion of participants with microbiological cure as determined by culture at rectal sites at test of cure visit. Day 6
Secondary The clinical cure rate of symptomatic gonorrhoea in male participants will be determined after administration of a single dose of zoliflodacin compared to a combination of single dose of ceftriaxone and azithromycin. Proportion of male participants with clinical cure at test of cure visit. Day 6
Secondary Microbiological cure rate of urogenital gonorrhoea will be determined among women and men respectively, after administration of a single dose of zoliflodacin compared to a combination of a single dose of ceftriaxone and azithromycin. Proportion of female and male participants respectively with microbiological cure as determined by culture at cervical or urethral site at test of cure visit. Day 6
Secondary Microbiological cure rate of Neisseria gonorrhoeae (NG) at urogenital sites will be determined. Proportion of participants with microbiological cure as determined by culture at urethral or cervical sites at the test of cure visit and for whom the baseline antimicrobial susceptibility profile indicated pre-existing resistance to antibiotics commonly used for Neisseria gonorrhoeae (NG) treatment. Day 6
Secondary Antimicrobial susceptibility profile will be determined of gonococcal strains isolated from participants with uncomplicated gonorrhoea at baseline and the test of cure visit. Antimicrobial susceptibility profile of gonococcal strains isolated at baseline and at test of cure visit. Day 6
Secondary The eradication rate of NG nucleic acid will be determined from urogenital rectal, pharyngeal specimens after administration of a single dose of zoliflodacin compared to a combination of a single dose of ceftriaxone and azithromycin. Proportion of participants with a negative NG NAAT from urethral or cervical, oropharyngeal and rectal sites at test of cure visit. Day 6
Secondary The plasma concentration will be evaluated (included Area Under the Curve (AUC) over 36 hours) after a single dose of zoliflodacin. Five PK timepoints post-treatment will be assessed. Day 2
See also
  Status Clinical Trial Phase
Completed NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A
Completed NCT03294395 - New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea Phase 3
Not yet recruiting NCT06428643 - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities N/A
Completed NCT03896776 - A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0) N/A
Completed NCT03718806 - Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin Phase 1
Completed NCT04010539 - A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Phase 3
Completed NCT00262106 - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Phase 3
Completed NCT00187902 - Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM N/A
Completed NCT00207506 - Lay Health Advisors for Sexually Transmitted Disease Prevention Phase 1/Phase 2
Completed NCT04553068 - Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection Phase 3
Active, not recruiting NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Phase 4
Completed NCT01465607 - Implementation of an Efficacious Intervention for High Risk Women in Mexico N/A
Terminated NCT00120770 - Cellulose Sulfate (CS) Gel and HIV in Nigeria Phase 3
Completed NCT02391233 - Multimedia WORTH With Black Drug-Involved Women on Probation N/A
Recruiting NCT05766904 - Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections Phase 3
Completed NCT04297436 - Gonococcal Vaccine Study in Key Populations in Kenya N/A
Completed NCT03098329 - Check it: A New Approach to Controlling Chlamydia Transmission in Young People N/A
Completed NCT02122094 - Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities N/A
Completed NCT01836445 - Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men N/A